Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Arab Association of Urology
Abstract
Many men have coexistent erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating both of these conditions independently. In this review we summarise the evidence supporting a link between ED and LUTS/BPH, and the results from key clinical studies related to the use of PDE5 inhibitors for treating both conditions. The results from these studies suggest that men who have both ED and LUTS/BPH, and are concerned about their sexual dysfunction, might benefit from single-agent, holistic treatment with a PDE5 inhibitor. © 2015 Arab Association of Urology.
Description
Keywords
Benign prostatic hyperplasia, Erectile dysfunction, Luts, Pde5 inhibitor, Finasteride, Placebo, Tadalafil, Article, Backache, Comorbidity, Coughing, Dizziness, Drug induced headache, Drug safety, Drug tolerability, Drug use, Dyspepsia, Follow up, Gastroesophageal reflux, Holistic care, Human, Hypertension, Lower urinary tract symptom, Monotherapy, Myalgia, Pathophysiology, Prostate hypertrophy, Randomized controlled trial (topic), Sexual dysfunction, Sinusitis, Urethra function